Diabetes News and Research

Latest Diabetes News and Research

Disabilities account for a quarter of U.S. adult health care costs

"Just over one-quarter of U.S. adult health care spending was associated with disability in 2006, according to a new study by researchers at RTI International and the U.S. Centers for Disease Control & Prevention," Insurance Journal reports.

11 Dec 2009

Kaiser Permanente: Women of Chinese and Korean heritage may develop diabetes during pregnancy

More than 10 percent of women of Chinese and Korean heritage may be at risk for developing diabetes during pregnancy, according to a Kaiser Permanente study of 16,000 women in Hawaii that appears in the December issue of the Ethnicity and Disease journal.

11 Dec 2009

Study may lead to improved, targeted therapies for cancer patients

A team of Princeton University scientists has produced a systematic listing of the ways a particular cancerous cell has "gone wrong," giving researchers a powerful tool that eventually could make possible new, more targeted therapies for patients.

11 Dec 2009

Avandia lawsuit: GSK's claims of privilege rejected

In a decision of importance to the case at hand and all cases involving claims of attorney-client or work product privilege, the Honorable Cynthia M. Rufe of the United States District Court for the Eastern District of Pennsylvania, in a decision of December 7, 2009, has ruled that GlaxoSmithKline (GSK), the manufacturer of the prescription diabetes medication Avandia, must produce dozens of documents that it withheld on claims of privilege.

11 Dec 2009

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Despite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

NIH launches a $37 million program to reduce obesity

The National Institutes of Health is launching a $37 million program that will use findings from basic research on human behavior to develop more effective interventions to reduce obesity.

11 Dec 2009

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

Aging is the single greatest risk factor for Alzheimer's disease. In their latest study, researchers at the Salk Institute for Biological Studies found that simply slowing the aging process in mice prone to develop Alzheimer's disease prevented their brains from turning into a neuronal wasteland.

10 Dec 2009

ARKRAY's Assure Platinum Blood Glucose Monitoring System receives FDA clearance

ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today received FDA clearance on the new Assure Platinum Blood Glucose Monitoring System.

10 Dec 2009

Abbott submits SIMCOR sNDA for two new dosage strengths

Abbott has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new dosage strengths of SIMCOR®, a cholesterol medication. SIMCOR is a fixed-dose combination of niacin extended-release and simvastatin.

10 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Fourth-quarter and full year fiscal 2009 results announced by Biodel

Biodel Inc. today reported financial results for the fourth quarter and fiscal year ended September 30, 2009.

10 Dec 2009

Roche launches new automated clinical laboratory system for HPV and CT/NG tests

Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs.

10 Dec 2009

Rituxan improves patients with previously untreated CLL, shows Phase III study CLL8

Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with Rituxan (rituximab) compared to chemotherapy alone.

10 Dec 2009

Ubiquitous health monitoring system can cut hospital visits and save lives

A ubiquitous health monitoring system that automatically alerted the patient's family or physician to problematic changes in the person's vital signs could cut hospital visits and save lives, according to Japanese researchers writing in the International Journal of Web and Grid Services.

10 Dec 2009

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

Cardiologists receive K23 research grant from NIH

Brian H. Annex, M.D., chief of the Division of Cardiovascular Medicine at the University of Virginia Health System, says he feels like the coach of a championship team. "Going three for three is truly extraordinary," he says with a mixture of pride and awe in his voice.

10 Dec 2009

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Seasonal flu vaccination rates among American adults have only slightly improved over last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus.

10 Dec 2009

Children exposed to tobacco smoke prenatally develop behavioral problems, shows study

The scientists observed that the impact of tobacco smoke was especially detrimental during gestation. The results of the study have been published in the current online issue of the renowned journal Environmental Health Perspectives.

10 Dec 2009